Effect of nifedipine gits on blood pressure, glucose metabolism, and lipid levels in hypertensive patients

Luis C. Ramirez, Michael Koffler, Carlos Arauz, Laura Schnurr-Breen, Philip Raskin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nifedipine, a calcium channel blocker widely used in the treatment of angina, has potent vasodilatory effects, making it an excellent anti-hypertensive agent. In a double-blind, placebo-controlled, paralleldose-response trial, we studied the effects of nifedipine GITS, a once-a-day dosage formulation, on blood pressure levels, serum lipid and lipoprotein levels, and glucose homeostasis in patients with mild essential hypertension. The blood pressure levels of the 23 patients treated with nifedipine GITS [systolic/diastolic (mean)] fell from 148 ± 4/98 ± 3 (115 ± 4) mmHg to 130 ± 13/85 ± 6 (100 ± 7 mmHg (P < 0.001). At the conclusion of the study, both diastolic and mean blood pressure levels in the nifedipine GITS group were significantly lower than those of the placebo group (P < 0.05). Nifedipine GITS had no effect on total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol levels or the glycosylated hemoglobin level (a measure of glucose homeostasis). Thus nifedipine GITS is effective in reducing blood pressure and has no adverse effects on lipid levels or glucose metabolism. We suggest that nifedipine GITS may be a treatment of choice for hypertensive patients who have other coronary risk factors, such as diabetes and hyperlipidemia.

Original languageEnglish (US)
Pages (from-to)468-477
Number of pages10
JournalCurrent Therapeutic Research
Volume52
Issue number3
DOIs
StatePublished - 1992

Fingerprint

Nifedipine
Lipid Metabolism
Blood Glucose
Blood Pressure
Glucose
Homeostasis
Placebos
Lipids
Glycosylated Hemoglobin A
Calcium Channel Blockers
Hyperlipidemias
LDL Cholesterol
HDL Cholesterol
Antihypertensive Agents
Lipoproteins
Triglycerides
Cholesterol
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of nifedipine gits on blood pressure, glucose metabolism, and lipid levels in hypertensive patients. / Ramirez, Luis C.; Koffler, Michael; Arauz, Carlos; Schnurr-Breen, Laura; Raskin, Philip.

In: Current Therapeutic Research, Vol. 52, No. 3, 1992, p. 468-477.

Research output: Contribution to journalArticle

Ramirez, Luis C. ; Koffler, Michael ; Arauz, Carlos ; Schnurr-Breen, Laura ; Raskin, Philip. / Effect of nifedipine gits on blood pressure, glucose metabolism, and lipid levels in hypertensive patients. In: Current Therapeutic Research. 1992 ; Vol. 52, No. 3. pp. 468-477.
@article{52cfc6724aba4df78125b467e74eb4dd,
title = "Effect of nifedipine gits on blood pressure, glucose metabolism, and lipid levels in hypertensive patients",
abstract = "Nifedipine, a calcium channel blocker widely used in the treatment of angina, has potent vasodilatory effects, making it an excellent anti-hypertensive agent. In a double-blind, placebo-controlled, paralleldose-response trial, we studied the effects of nifedipine GITS, a once-a-day dosage formulation, on blood pressure levels, serum lipid and lipoprotein levels, and glucose homeostasis in patients with mild essential hypertension. The blood pressure levels of the 23 patients treated with nifedipine GITS [systolic/diastolic (mean)] fell from 148 ± 4/98 ± 3 (115 ± 4) mmHg to 130 ± 13/85 ± 6 (100 ± 7 mmHg (P < 0.001). At the conclusion of the study, both diastolic and mean blood pressure levels in the nifedipine GITS group were significantly lower than those of the placebo group (P < 0.05). Nifedipine GITS had no effect on total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol levels or the glycosylated hemoglobin level (a measure of glucose homeostasis). Thus nifedipine GITS is effective in reducing blood pressure and has no adverse effects on lipid levels or glucose metabolism. We suggest that nifedipine GITS may be a treatment of choice for hypertensive patients who have other coronary risk factors, such as diabetes and hyperlipidemia.",
author = "Ramirez, {Luis C.} and Michael Koffler and Carlos Arauz and Laura Schnurr-Breen and Philip Raskin",
year = "1992",
doi = "10.1016/S0011-393X(05)80423-0",
language = "English (US)",
volume = "52",
pages = "468--477",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Effect of nifedipine gits on blood pressure, glucose metabolism, and lipid levels in hypertensive patients

AU - Ramirez, Luis C.

AU - Koffler, Michael

AU - Arauz, Carlos

AU - Schnurr-Breen, Laura

AU - Raskin, Philip

PY - 1992

Y1 - 1992

N2 - Nifedipine, a calcium channel blocker widely used in the treatment of angina, has potent vasodilatory effects, making it an excellent anti-hypertensive agent. In a double-blind, placebo-controlled, paralleldose-response trial, we studied the effects of nifedipine GITS, a once-a-day dosage formulation, on blood pressure levels, serum lipid and lipoprotein levels, and glucose homeostasis in patients with mild essential hypertension. The blood pressure levels of the 23 patients treated with nifedipine GITS [systolic/diastolic (mean)] fell from 148 ± 4/98 ± 3 (115 ± 4) mmHg to 130 ± 13/85 ± 6 (100 ± 7 mmHg (P < 0.001). At the conclusion of the study, both diastolic and mean blood pressure levels in the nifedipine GITS group were significantly lower than those of the placebo group (P < 0.05). Nifedipine GITS had no effect on total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol levels or the glycosylated hemoglobin level (a measure of glucose homeostasis). Thus nifedipine GITS is effective in reducing blood pressure and has no adverse effects on lipid levels or glucose metabolism. We suggest that nifedipine GITS may be a treatment of choice for hypertensive patients who have other coronary risk factors, such as diabetes and hyperlipidemia.

AB - Nifedipine, a calcium channel blocker widely used in the treatment of angina, has potent vasodilatory effects, making it an excellent anti-hypertensive agent. In a double-blind, placebo-controlled, paralleldose-response trial, we studied the effects of nifedipine GITS, a once-a-day dosage formulation, on blood pressure levels, serum lipid and lipoprotein levels, and glucose homeostasis in patients with mild essential hypertension. The blood pressure levels of the 23 patients treated with nifedipine GITS [systolic/diastolic (mean)] fell from 148 ± 4/98 ± 3 (115 ± 4) mmHg to 130 ± 13/85 ± 6 (100 ± 7 mmHg (P < 0.001). At the conclusion of the study, both diastolic and mean blood pressure levels in the nifedipine GITS group were significantly lower than those of the placebo group (P < 0.05). Nifedipine GITS had no effect on total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol levels or the glycosylated hemoglobin level (a measure of glucose homeostasis). Thus nifedipine GITS is effective in reducing blood pressure and has no adverse effects on lipid levels or glucose metabolism. We suggest that nifedipine GITS may be a treatment of choice for hypertensive patients who have other coronary risk factors, such as diabetes and hyperlipidemia.

UR - http://www.scopus.com/inward/record.url?scp=0026808873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026808873&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80423-0

DO - 10.1016/S0011-393X(05)80423-0

M3 - Article

AN - SCOPUS:0026808873

VL - 52

SP - 468

EP - 477

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 3

ER -